News & Analysis as of July 30, 2025

CAFC

+ Follow

5 Key Takeaways | Making Sense of §102 Public Use and On Sale Bars to Patentability
Building a Cost-Effective Global Patent Portfolio Using the Netherlands
3 Key Takeaways | Third party Prior Art Submissions at USPTO
Conflicting Application in China’s Patent System
Patent Right Evaluation Report in China’s Patent System
Stages of Patent Invalidation Proceedings
The Patent Process | Interview with Patent Attorney, Robert Greenspoon
Secondary Considerations of Non-Obviousness - Patents: Post-Grant Podcast
Nonpublication Requests For Patent Applications: Disadvantages
Podcast: IP Life Sciences Landscape: Aiding Orange and Purple Book Patent Owners in Developing PTAB Survival Skills
Is The Deck Stacked Against Patent Owners In The PTAB?
What the First-to-File Patent Change Means (And What IP Strategists Should Do About It)

Agilent Technologies, Inc. v. Synthego Corp. (Fed. Cir. 2025)

McDonnell Boehnen Hulbert & Berghoff LLP on 6/17/2025

An argument could be made that one of the most significant Supreme Court decisions in U.S. patent law in the last thirty years was Dickinson v. Zurko. In that case the Court held that the Federal Circuit was bound by the...more

Federal Circuit Reaffirms “Carried Forward” Requirement for Provisional Priority in Reexams and Reissues

Sterne, Kessler, Goldstein & Fox P.L.L.C. on 4/30/2025

Requesters should make sure to double cite to non-provisional and provisional if they require a provisional filing date for prior art....more

2 Results

View per page

Page: of 1

Prior Art › Amgen v Sanofi › CAFC

Agilent Technologies, Inc. v. Synthego Corp. (Fed. Cir. 2025)

Federal Circuit Reaffirms “Carried Forward” Requirement for Provisional Priority in Reexams and Reissues

"My best business intelligence, in one easy email…"